Edwards Lifesciences Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Edwards Lifesciences Corp 公司

Edwards Lifesciences Corporation 是一家全球性結構性心臟創新公司。該公司致力於以患者爲中心的結構性心臟病醫療創新，並投資於研發，以改變結構性心臟病患者的護理。其產品分爲幾類，包括經導管主動脈瓣置換術 (TAVR)、經導管二尖瓣和三尖瓣治療 (TMTT) 和外科結構性心臟 (外科)。該公司開發了經導管心臟瓣膜置換技術，旨在以微創方式置換主動脈瓣膜。Edwards SAPIEN 系列瓣膜包括 Edwards SAPIEN 3、Edwards SAPIEN 3 Ultra 和 Edwards SAPIEN 3 Ultra RESILIA 系統，這些系統是基於導管的治療方法，用於治療嚴重的症狀性主動脈瓣狹窄。其 PASCAL PRECISION 和 Cardioband 經導管瓣膜修復系統已在歐洲上市，用於二尖瓣和三尖瓣修復。

公司簡介

公司代碼EW

公司名稱Edwards Lifesciences Corp

上市日期Mar 27, 2000

CEOMr. Bernard J. Zovighian

員工數量15800

證券類型Ordinary Share

年結日Mar 27

公司地址One Edwards Way

城市IRVINE

上市交易所NYSE Consolidated

國家United States of America

郵編92614

電話19492502500

網址https://www.edwards.com

公司代碼EW

上市日期Mar 27, 2000

CEOMr. Bernard J. Zovighian

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

業務USD

名稱

營收

佔比

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

地區USD

名稱

營收

佔比

United States

838.90M

59.38%

Europe

341.80M

24.19%

Rest of the world

150.20M

10.63%

Japan

81.80M

5.79%

業務

地區

業務USD

名稱

營收

佔比

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Global Advisors (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

其他

71.70%

持股股東

佔比

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Global Advisors (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

其他

71.70%

股東類型

持股股東

佔比

Investment Advisor

43.47%

Investment Advisor/Hedge Fund

29.29%

Hedge Fund

6.66%

Research Firm

2.13%

Pension Fund

2.13%

Bank and Trust

1.93%

Sovereign Wealth Fund

1.35%

Individual Investor

0.92%

Endowment Fund

0.82%

其他

11.29%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

2595

528.14M

89.95%

-20.66M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

68.94M

11.75%

+70.46K

+0.10%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

32.28M

5.5%

+544.18K

+1.71%

Mar 31, 2025

State Street Global Advisors (US)

25.78M

4.4%

-25.16K

-0.10%

Mar 31, 2025

JP Morgan Asset Management

16.37M

2.79%

+5.61M

+52.12%

Mar 31, 2025

Wellington Management Company, LLP

29.13M

4.97%

-4.08M

-12.27%

Mar 31, 2025

Citadel Advisors LLC

13.38M

2.28%

+3.96M

+42.09%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.68M

2.16%

-970.48K

-7.11%

Mar 31, 2025

Jennison Associates LLC

10.09M

1.72%

+2.58M

+34.31%

Mar 31, 2025

Walter Scott & Partners Ltd.

9.06M

1.54%

-347.38K

-3.69%

Mar 31, 2025

持股ETF

更新時間: 9月6日週六

機構名稱

佔比

iShares U.S. Medical Devices ETF

4.91%

Future Fund Long/Short ETF

3.53%

iShares Health Innovation Active ETF

3.33%

Hennessy Sustainable ETF

3.29%

Global X Aging Population ETF

3.19%

First Trust Indxx Medical Devices ETF

2.24%

SPDR S&P Health Care Equipment ETF

2.05%

Brown Advisory Flexible Equity ETF

1.99%

Tema Heart & Health ETF

1.93%

Invesco S&P 500 Equal Weight Health Care ETF

1.84%

iShares U.S. Medical Devices ETF

佔比4.91%

Future Fund Long/Short ETF

佔比3.53%

iShares Health Innovation Active ETF

佔比3.33%

Hennessy Sustainable ETF

佔比3.29%

Global X Aging Population ETF

佔比3.19%

First Trust Indxx Medical Devices ETF

佔比2.24%

SPDR S&P Health Care Equipment ETF

佔比2.05%

Brown Advisory Flexible Equity ETF

佔比1.99%

Tema Heart & Health ETF

佔比1.93%

Invesco S&P 500 Equal Weight Health Care ETF

佔比1.84%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

May 07, 2020

Split

1→3

公告日期

類型

比率

May 07, 2020

Split

1→3

Edwards Lifesciences Corp

75.090USD

Edwards Lifesciences Corp

75.090

概覽

公司

財務

分析